团队依托的上海市肺科医院呼吸与危重症医学科，为国家临床重点专科、国家呼吸与危重症医学科(PCCM)专科规范化建设三级医院示范单位、上海市重中之重临床重点学科，上海市临床重点专科、全国首批呼吸危重症专培基地，上海市首批呼吸专培基地、同济大学呼吸病研究所所长单位。。团队致力于非结核分枝杆菌（NTM）及真菌肺部感染的研究，尤其以NTM肺病诊疗和NTM耐药机制的研究为特色，目前有教授2人，副教授1人，博导3人；临床医师10人；博士后2人，在读研究生11人，每年新招录研究生≥3人，在研课题经费1000余万元。

1.   上海市科委生物医药研究专项项目，抗非结核分枝杆菌新型硼化合物类药物MRX-5的临床前研究，23S11901400，2023-04至2026-03，740万元，在研，主持

2.   国家自然科学基金委员会，面上项目，81971973，铁摄取转录因子FurB调控VII型分泌系统介导脓肿分枝杆菌对贝达喹啉耐药的机制研究，2020-01至2023-12，54万元，已结题，主持

3.   上海市科学技术委员会，自然科学基金，22ZR1452000，MmpS5/Mmpl5抑制DNA错配修复基因MA-nucS介导脓肿分枝杆菌对贝达喹啉耐药的机制研究，2022-04至2025-05，20万元，在研，主持

4.   上海市科学技术委员会，西医引导项目，18411970600，基于CRISPER原理的SHERLOCK新技术用于非结核分枝杆菌肺病的快速诊断，2018-08至2021-09，20万元，已结题，主持

5.   国家自然科学基金委员会，面上项目，81672063，yrbE基因突变导致脓肿分枝杆菌对克拉霉素耐药的机制研究，2017-01至2020-12，57万元，已结题，主持

6.   上海申康医院发展中心，申康市级医院新兴前沿技术联合攻关项目，SHDC12017113，基于GenSeizer特征性基因捕获策略指导非结核分枝杆菌肺病诊断和治疗的临床研究，2017-10至2020-09，150万元，已结题，主持

7.   上海市卫生和计划生育委员会，重点项目，201546347，上海地区脓肿分枝杆菌分子分型及临床影像分析，2016-01至2018-12，15万元，已结题，主持

1.   上海市科委生物医药研究专项项目，抗非结核分枝杆菌新型硼化合物类药物MRX-5的临床前研究，23S11901400，2023-04至2026-03，740万元，在研，主持

2.   国家自然科学基金委员会，面上项目，81971973，铁摄取转录因子FurB调控VII型分泌系统介导脓肿分枝杆菌对贝达喹啉耐药的机制研究，2020-01至2023-12，54万元，已结题，主持

3.   上海市科学技术委员会，自然科学基金，22ZR1452000，MmpS5/Mmpl5抑制DNA错配修复基因MA-nucS介导脓肿分枝杆菌对贝达喹啉耐药的机制研究，2022-04至2025-05，20万元，在研，主持

4.   上海市科学技术委员会，西医引导项目，18411970600，基于CRISPER原理的SHERLOCK新技术用于非结核分枝杆菌肺病的快速诊断，2018-08至2021-09，20万元，已结题，主持

5.   国家自然科学基金委员会，面上项目，81672063，yrbE基因突变导致脓肿分枝杆菌对克拉霉素耐药的机制研究，2017-01至2020-12，57万元，已结题，主持

6.   上海申康医院发展中心，申康市级医院新兴前沿技术联合攻关项目，SHDC12017113，基于GenSeizer特征性基因捕获策略指导非结核分枝杆菌肺病诊断和治疗的临床研究，2017-10至2020-09，150万元，已结题，主持

7.   上海市卫生和计划生育委员会，重点项目，201546347，上海地区脓肿分枝杆菌分子分型及临床影像分析，2016-01至2018-12，15万元，已结题，主持

代表性论著：

1.      NTM相关JCR I区SCI论文（时间倒序，#第一/共一作者，*通讯/共通讯作者）

①     Fan J#, Tan Z#, He S#, Li A, Jia Y, LiJ, Zhang Z*, Li B*, Chu H*. TBAJ-587, a Novel Diarylquinoline, Is ActiveAgainst Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy. 2024Sep; (accepted). (IF 4.1)

②     Fan J#, Jia Y#, He S, Tan Z, Li A, Li J,Zhang Z, Li B*, Chu H*. GlnR Activated Transcriptionof Nitrogen Metabolic Pathway Genes Facilitates Biofilm Formation byMycobacterium abscessus. Int J Antimicrob Agents. 2023 Nov 3:107025. doi:10.1016/j.ijantimicag.2023.107025. Epub 2023 Nov 4. PMID: 37926271. (IF 4.9)

③     Li B#, He S#, Tan Z#, Li A, Fan J, ZhaoL, Zhang Z, Chu H*. Impaired ESX-3 Induces Bedaquiline Persistence inMycobacterium abscessus Growing Under Iron-limited Conditions. Small Methods.2023 Jun 8:e2300183. doi: 10.1002/smtd.202300183. Epub 2023 Jun 8. PMID:37291735. (IF 10.7)

④     Wu W#, He S#, Li A#, Guo Q, Tan Z, LiuS, Wang X, Zhang Z, Li B*, Chu H*. A Novel Leucyl-tRNA Synthetase Inhibitor,MRX-6038, Expresses Anti-Mycobacterium abscessus Activity In Vitro and In Vivo.Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0060122. doi:10.1128/aac.00601-22. Epub 2022 Aug 15. PMID: 35969055; PMCID: PMC9487484. (IF 4.1)

⑤     Li B#, Zhang Y#, Guo Q#, He S, Fan J, XuL, Zhang Z, Wu W*, Chu H*. Antibacterial peptide RP557 increases theantibiotic sensitivity of Mycobacterium abscessus by inhibiting biofilmformation. Sci Total Environ. 2022 Feb 10;807(Pt 3):151855. doi:10.1016/j.scitotenv.2021.151855. Epub 2021 Nov 20. PMID: 34813807. (IF 8.2)

⑥     Guo Q#, Xu L#, Tan F, Zhang Y, Fan J,Wang X, Zhang Z, Li B*, Chu H*. A NovelOxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessusActivity In Vitro. Antimicrob Agents Chemother. 2021 Oct18;65(11):e0088921. doi: 10.1128/AAC.00889-21. Epub 2021 Aug 30. PMID:34460305; PMCID: PMC8522767. (IF 4.1)

⑦    Guo Q, Zhang Y, Fan J, ZhangH, Zhang Z, Li B*, Chu H*. MAB_2355c Confers Macrolide Resistance inMycobacterium abscessus by Ribosome Protection. Antimicrob Agents Chemother.2021 Jul 16;65(8):e0033021. doi: 10.1128/AAC.00330-21. Epub 2021 Jul 16. PMID:34097497; PMCID: PMC8373217. (IF 4.1) 

⑧    Li B#, Xu L#, Guo Q, Chen J, Zhang Y,Huang W, Zhang Z, Han L, Xu X*, Chu H*. GenSeizer: a Multiplex PCR-BasedTargeted Gene Sequencing Platform for Rapid and Accurate Identification ofMajor Mycobacterium Species. J Clin Microbiol. 2021 Jan 21;59(2):e00584-20.doi: 10.1128/JCM.00584-20. PMID: 33177124; PMCID: PMC8111139. (IF 6.1)

⑨    Zhang S#, Zou Y#, Guo Q,Chen J, Xu L, Wan X, Zhang Z, Li B*, Chu H*. AR-12 Exhibits Direct andHost-Targeted Antibacterial Activity toward Mycobacterium abscessus.Antimicrob Agents Chemother. 2020 Jul 22;64(8):e00236-20. doi:10.1128/AAC.00236-20. PMID: 32482678; PMCID: PMC7526805. (IF 4.1) 

⑩    Li B#, Ye M#, Zhao L, Guo Q,Chen J, Xu B, Zhan M, Zhang Y, Zhang Z, Chu H*. GlycopeptidolipidGenotype Correlates With the Severity of Mycobacterium abscessus Lung Disease.J Infect Dis. 2020 Mar 16;221(Suppl 2):S257-S262. doi: 10.1093/infdis/jiz475.PMID: 32176786. (IF 5.0)

⑪    Ye M#, Xu L#, Zou Y#, Li B,Guo Q, Zhang Y, Zhan M, Xu B, Yu F, Zhang Z*, Chu H*. Molecular Analysisof Linezolid-Resistant Clinical Isolates of Mycobacterium abscessus. AntimicrobAgents Chemother. 2019 Jan 29;63(2):e01842-18. doi: 10.1128/AAC.01842-18. PMID:30478161; PMCID: PMC6355594. (IF 4.1) 

⑫    Li B#, Ye M#, Guo Q#, ZhangZ, Yang S, Ma W, Yu F*, Chu H*. Determination of MIC Distribution andMechanisms of Decreased Susceptibility to Bedaquiline among Clinical Isolatesof Mycobacterium abscessus. Antimicrob Agents Chemother. 2018 Jun26;62(7):e00175-18. doi: 10.1128/AAC.00175-18. PMID: 29712658; PMCID: PMC6021634.(IF 4.1) 

⑬    Guo Q, Chu H*, Ye M*,Zhang Z, Li B, Yang S, Ma W, Yu F. The Clarithromycin Susceptibility GenotypeAffects the Treatment Outcome of Patients with Mycobacterium abscessus LungDisease. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02360-17. doi:10.1128/AAC.02360-17. PMID: 29483126; PMCID: PMC5923093. (IF 4.1) 

⑭    Li B#, Yang S#, Chu H*,Zhang Z*, Liu W, Luo L, Ma W, Xu X. Relationship between AntibioticSusceptibility and Genotype in Mycobacterium abscessus Clinical Isolates. FrontMicrobiol. 2017 Sep 14;8:1739. doi: 10.3389/fmicb.2017.01739. PMID: 28959242;PMCID: PMC5603792. (IF 4.0)

⑮    Luo L#, Liu W#, Li B#, Li M,Huang D, Jing L, Chen H, Yang J, Yue J, Wang F, Chu H*, Zhang Z*. Evaluation of Matrix-Assisted Laser Desorption Ionization-Timeof Flight Mass Spectrometry for Identification of Mycobacterium abscessusSubspecies According to Whole-Genome Sequencing. J Clin Microbiol. 2016Dec;54(12):2982-2989. doi: 10.1128/JCM.01151-16. Epub 2016 Sep 28. PMID:27682129; PMCID: PMC5121389. (IF 6.1)

2.       真菌相关SCI论文（时间倒序，#第一/共一作者，*通讯/共通讯作者）

①   Zheng Q#, Xiao S#, Ji L#, Bing J#, Li B, Han L, Chu H*, Huang G*. Firstcase of fungemia caused by a rare and pan-echinocandin resistant yeast Sporopachydermia lactativora in China.Mycology. 2024:1-5. doi: 10.1080/21501203.2024.2418111. (IF 4.6)

②   Zheng T#, Ji L#, Chen Y#, Cao C, Bing J, Hu T, Zheng Q, Wu D, Chu H*, Huang G*. Biology and genetic diversity of Candida krusei isolates from fermentedvegetables and clinical samples in China. Virulence.2024 Oct 2:2411543. doi: 10.1080/21505594.2024.2411543. Epub ahead of print.PMID: 39359062. (IF 8.4)

③   Bing J#, Guan Z#, Zheng T, Ennis CL, Nobile CJ, Chen C, Chu H*, Huang G*. Rapid evolution of an adaptive multicellular morphology of Candida aurisduring systemic infection. Nat Commun. 2024 Mar 16;15(1):2381. doi:10.1038/s41467-024-46786-8. PMID: 38493178; PMCID: PMC10944540. (IF 14.7)

④  Bing J#, DuH#, Guo P#, Hu T#, Xiao M, Lu S, Nobile CJ, Chu H*, Huang G*. Candida auris-associated hospitalizations and outbreaks,China, 2018-2023. Emerg Microbes Infect. 2024 Dec;13(1):2302843. doi:10.1080/22221751.2024.2302843. Epub 2024 Jan 18. PMID: 38238874; PMCID:PMC10802803. (IF 8.4)

⑤   Hu T, Wang S, Bing J, Zheng Q, Du H, Li C, Guan Z, Bai FY, Nobile CJ, Chu H*, Huang G*. Hotspot mutations andgenomic expansion of ERG11 are major mechanisms of azole resistance inenvironmental and human commensal isolates of Candida tropicalis. Int JAntimicrob Agents. 2023 Dec;62(6):107010. doi:10.1016/j.ijantimicag.2023.107010. Epub 2023 Oct 18. PMID: 37863341. (IF 4.9)

3.      其他SCI论文（时间倒叙，#第一/共一作者，*通讯/共通讯作者）

⑥   Li A, He S, Li J, Zhang Z, Li B*, Chu H*. Omadacycline,Eravacycline, and Tigecycline Express Anti-Mycobacterium abscessus Activity InVitro. Microbiol Spectr. 2023 May 4:e0071823. doi: 10.1128/spectrum.00718-23. Epub2023 May 4. PMID: 37140428 ; PMCID: PMC10269442. (IF 3.7)

⑦  He S#, Guo Q#, Zhao L#, Xu L, Fan J, Wu W,Zhang Z, Li B*, Chu H*. Sitafloxacin Expresses Potent Anti-Mycobacteriumabscessus Activity. Front Microbiol. 2022 Jan 6;12:779531. doi:10.3389/fmicb.2021.779531. PMID: 35069482; PMCID: PMC8770805. (IF 4.0)

⑧   Chen J#, Zhang H#, Guo Q, He S, Xu L, Zhang Z, Ma J*, Chu H*.In vitro activity of rifabutin against Mycobacterium abscessus, clinicalisolates. Clin Exp Pharmacol Physiol. 2022 Jul;49(7):767-775. doi:10.1111/1440-1681.13651. Epub 2022 Jun 5. PMID: 35531776. (IF 2.4)

⑨   He S#, Zou Y#, Zhan M#, Guo Q, Zhang Y, Zhang Z, Li B, Zhang S*,Chu H*. Zinc Chelator N,N,N',N'-Tetrakis(2-Pyridylmethyl)EthylenediamineReduces the Resistance of Mycobacterium abscessus to Imipenem. Infect DrugResist. 2020 Aug 18;13:2883-2890. doi: 10.2147/IDR.S267552. PMID: 32903882;PMCID: PMC7445496. (IF 2.9)

⑩  Guo Q, Chen J, Zhang S, ZouY, Zhang Y, Huang D, Zhang Z, Li B*, Chu H*. Efflux PumpsContribute to Intrinsic Clarithromycin Resistance in Clinical, Mycobacteriumabscessus Isolates. Infect Drug Resist. 2020 Feb 12;13:447-454. doi:10.2147/IDR.S239850. PMID: 32104016; PMCID: PMC7024787. (IF 2.9)

⑪  Li B#, Guo Q#, Mao Y#, ZouY, Zhang Y, Zhang Z*, Chu H*. Genetic Evolution of Mycobacteriumabscessus Conferring Clarithromycin Resistance during Long-Term AntibioticTherapy. Can Respir J. 2020 Mar 28;2020:7623828. doi: 10.1155/2020/7623828.PMID: 32300380; PMCID: PMC7142343. (IF 2.1)

⑫   Chen J#, Zhao L#, Mao Y#, Ye M, Guo Q, Zhang Y, Xu L, Zhang Z,Li B*, Chu H*. Clinical Efficacy and Adverse Effects of Antibiotics Usedto Treat Mycobacterium abscessus Pulmonary Disease. Front Microbiol. 2019 Aug23;10:1977. doi: 10.3389/fmicb.2019.01977. PMID: 31507579; PMCID:PMC6716072. (IF 4.0)

⑬  Wu M#, Li B#, Guo Q, Xu L,Zou Y, Zhang Y, Zhan M, Xu B, Ye M, Yu F, Zhang Z*, Chu H*. Detectionand molecular characterisation of amikacin-resistant Mycobacterium abscessusisolated from patients with pulmonary disease. J Glob Antimicrob Resist. 2019Dec;19:188-191. doi: 10.1016/j.jgar.2019.05.016. Epub 2019 May 20. PMID:31121335. (IF 3.7)

⑭  Liu W#, Li B#, Chu H*,Zhang Z*, Luo L#, Ma W, Yang S, Guo Q. Rapid detection of mutations in erm(41)and rrl associated with clarithromycin resistance in Mycobacterium abscessuscomplex by denaturing gradient gel electrophoresis. J Microbiol Methods. 2017Dec;143:87-93. doi: 10.1016/j.mimet.2017.10.010. Epub 2017 Oct 24. PMID:29079298. (IF 1.7)

4.      中文论文

①    李冰, 郭琦, 褚海青* . 奈诺沙星对脓肿分枝杆菌体外抗菌活性的评价. 中华结核和呼吸杂志,2021, 44(11): 19-24.

发明专利：

1.  褚海青；叶美萍；李冰；徐晓刚；江建平；郭琦；张哲民，一种基因序列组合物及其在制备分枝杆菌肺病检测试剂盒中的应用，授权时间：2020-6-5，专利号：ZL 201811505582.3；

2.  褚海青，建立脓肿分枝杆菌RUO 数据库和构建亚型超级图谱的方法，授权时间：2019-8-16，专利号：ZL 201611024252.0。

学术奖励：

褚海青(1/9); 非结核分枝杆菌感染诊疗新策略的开发, 上海市医学会, 上海医学科技奖三等奖,2022 (褚海青; 李冰; 张哲民; 郭琦; 余方友; 顾瑾; 张亚楠; 赵兰; 徐丽云)